SMART Medical Systems Ltd., a developer and manufacturer of innovative endoscopy products, today reported positive data from a multicenter clinical study (NCT 04708951) comparing the adenoma detection rate (ADR) of its FDA-cleared G-EYE® balloon technology against ENDOCUFF VISION® (ECV) technology in patients undergoing screening or surveillance colonoscopy. Results from this randomized trial, the first head-to-head comparison of these two colonoscopy mechanical enhancement devices, showed that the ADR, particularly for advanced and large adenomas, was higher for the G-EYE® balloon than for the ECV attachment. Seth Gross, MD, Professor, Department of Medicine at NYU Grossman School of Medicine, Clinical Chief, Division of Gastroenterology and Hepatology at NYU Langone Health, and co-author on the abstract, presented the data in an oral session at ACG 2021, which is taking place October 22-27 in Las Vegas (ACG 2021, Presidential Plenary Session 1, Abstract #S233).
Trending
- Cancer risk comparable across advanced IBD therapies in claims analysis (GI & Hepatology News)
- Independent practice on the road to extinction: Why the next generation won’t own the stethoscope, let alone the building (Medical Economics)
- Fecal Burden on CT Weakly Correlates with Bowel Function in Adults and is Poorly Associated with Clinical Symptoms (Digestive Diseases and Sciences)
- Cook Medical issues medical device correction for Hemospray Endoscopic Hemostat (AGA)
- Medicare physician pay reform 2027: Patients First Act and 4 other bills explained (Physicians Practice)
- FDA Advisory Committee Votes In Favor of Approval of GRAIL’s Galleri® Multi-Cancer Early Detection Test (PR Newswire)
- Batteries that safely break down in the GI tract could improve ingestible devices (Medical Xpress)
- Management of Obesity: Review of Adjunctive Therapies and Clinical Management Pearls (Gastroenterology)
